• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

    86.30 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Mirum Pharmaceuticals, Inc. - common stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience
    NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health,... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Energy
    Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗
    Via Chartmill
    News headline image
    Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗
    Mirum (MIRM) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy ↗
    Via Chartmill
    Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup ↗
    Via Chartmill
    MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
    Via Chartmill
    Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' ↗
    Via Stocktwits
    News headline image
    ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗
    Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision... 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
    Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
    Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
     
    Via Benzinga
    News headline image
    Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
    This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗
    The drugmaker is doing nearly everything else right. 
    Via The Motley Fool
    News headline image
    Is Mirum Pharmaceuticals About to Soar in 2026? ↗
    The future looks bright for this high-flying biotech stock. 
    Via The Motley Fool
    News headline image
    A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)
    Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage... 
    Via PredictStreet
    Topics Economy Initial Public Offering
    News headline image
    3 Top Growth Stocks to Buy in the First Half of 2026 ↗
    Don't wait too long to make a decision on these three stocks. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 ↗
    Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right ↗
    Not all of these predictions may come true. But at least a few of them will likely do so. 
    Via The Motley Fool
    Topics Artificial Intelligence Economy
    News headline image
    Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now ↗
    These predictions were easy. 
    Via The Motley Fool
    News headline image
    Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗
    Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 ↗
    Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
    A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
    Via The Motley Fool
    News headline image
    MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
    Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout. 
    Via Chartmill
    News headline image
    Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗
    Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock ↗
    One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds. 
    Via The Motley Fool
    News headline image
    Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge ↗
    This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline. 
    Via The Motley Fool
    News headline image
    What Analysts Are Saying About Mirum Pharmaceuticals Stock ↗
     
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup ↗
    Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities. 
    Via Chartmill
    News headline image
    8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know ↗
     
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup ↗
    Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout. 
    Via Chartmill
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.